Why Uveal Melanoma Is Different, and What That Means for Treatment

• Uveal melanoma’s distinct biology has made it resist systemic treatment
• HLA-A*02:01–negative patients have historically had limited options
• Past choices: liver-directed therapy, off-label combos, or clinical trials
• OptimUM-02 tested darovasertib plus crizotinib vs. investigator’s choice
• More emerging options are making treatment sequencing more complex

If you’ve ever been told “uveal melanoma isn’t like skin melanoma,” you’re not alone. That difference is at the heart of a recent OncLive On Air podcast interview with Dr. Marlana M. Orloff. I wanted to share what it covers, especially for those of us navigating metastatic disease.

Why this cancer is so hard to treat

In the interview, Dr. Orloff talks about the distinct biology of uveal melanoma and why it has historically resisted systemic treatment, meaning treatments that work throughout the whole body. The written summary doesn’t explain what makes the biology different, so if that question is on your mind, the full episode is the place to hear her explanation.

What options looked like for HLA-negative patients

This part may feel familiar to many of us. Dr. Orloff focused on patients who are HLA-A*02:01–negative. Before the phase 2/3 OptimUM-02 trial, she noted, this group had limited choices: liver-directed therapies such as percutaneous hepatic perfusion, off-label combinations of immune checkpoint inhibitors, or enrolling in a clinical trial. The summary doesn’t explain what HLA type is or how it’s determined. If you’re not sure of yours or why it matters, that’s a great question for your care team.

The OptimUM-02 trial

Dr. Orloff also walks through the design and efficacy findings of the trial. It compared a combination of darovasertib, an oral PKC inhibitor, plus crizotinib (Xalkori), a MET inhibitor, against investigator’s choice in HLA-A*02:01–negative patients who had not yet received treatment. The written summary doesn’t share the actual results, so I won’t guess at them here. You’ll need to listen to the episode to hear what the trial found.

A growing, and more complicated, set of choices

Here’s something that feels genuinely hopeful: the conversation turns to how deciding the order of treatments is getting more complex as new options appear. The options she mentions include tebentafusp-tebn (Kimmtrak) for HLA-A*02:01–positive patients, liver-directed and combination approaches, and an investigational TCR-engineered T-cell therapy called anzutresgene autoleucel, which targets PRAME. The summary doesn’t explain how these therapies work, so terms like PKC, MET and PRAME are worth asking your oncologist about.

Why this matters to us

Having more options means more decisions, and that can feel overwhelming. The takeaway for me is that uveal melanoma treatment is becoming more personalized. Knowing your HLA status and having open conversations with your care team about what comes first, and what comes next, matters more than ever.

Listen to the full interview here: Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma

You don’t have to figure this out alone

Ocular melanoma is rare, and treatment decisions can feel isolating. Have you had to choose between liver-directed therapy, a clinical trial or another path? Do you know your HLA type, and did it shape your options? Share your story in the comments. Someone reading this may be facing the same crossroads today. And please pass this post along to help raise awareness. Every conversation brings our community closer together.